Airway Therapeutics Announces Filing with NIH to Evaluate AT-100 as a Therapy for Novel Coronavirus
Data demonstrate AT-100 (rhSP-D) – novel human recombinant protein – reduces infection in a range of bacteria and virus-driven respiratory diseases with potential to treat COVID-19 CINCINNATI, OH (March 11, 2020) – Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with …
Airway Therapeutics Closes $15.5 Million Series C Financing to Advance Preclinical and Clinical Research and Development Programs to Prevent and Treat Serious Respiratory Diseases
Initiating bronchopulmonary dysplasia (BPD) clinical trial in very preterm infants in 2020 with orphan drug designation Advancing preclinical research in influenza, RSV, cystic fibrosis Bolsters executive leadership with key finance and regulatory hires CINCINNATI, OH (January 8, 2020) – Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the injury …
Airway Therapeutics Announces Appointment of Chief Medical Officer
(Cincinnati, OH—August 24, 2018) Airway Therapeutics, LLC (“Airway”), a biotechnology company focused on developing new interventions for acute and chronic lung diseases, announces the appointment of Paul Kingma, MD, PhD to the position of Chief Medical Officer (“CMO”) as of August 1, 2018 in preparation for clinical development of AT-100, a recombinant form of human …
Airway Therapeutics Closes $11M Series B Round of Financing
(Cincinnati, OH– April 17, 2018) Airway Therapeutics, a biotechnology company focused on developing new interventions for acute and chronic lung diseases has secured $11 million in Series B financing from new and existing investors. The financing comes as Airway Therapeutics steadily meets milestones in the development of its lead product AT-100, a recombinant form of …
Airway Therapeutics, LLC Obtains License on Glycotope Cell Line
Core Manufacturing Technology is Key Milestone on Airway’s Path to Market Cincinnati, Ohio, 11 September 2017- Airway Therapeutics, LLC, [Airway] a biotech company focused on developing new interventions for acute and chronic lung diseases, today announced an exclusive licensing agreement with the German biotechnology company, Glycotope GmbH [Glycotope]. Under the terms of this agreement, Airway …
Airway Therapeutics Closes $6.3M in Finance Round
Financing furthers Company’s efforts to improve outcomes for very premature infants Cincinnati OH—March 6, 2017 Airway Therapeutics, a biotechnology company focused on developing new interventions for acute and chronic lung diseases, beginning with premature infants, has secured $6.3 million in bridge financing from new and existing investors. Cincinnati Children’s Hospital Medical Center, CincyTech and Queen …
Airway Therapeutics Raises $4.6 Million in Series A Funding
Financing Follows FDA Orphan Designation for Startup Working to Improve Outcomes for Very Premature Infants (Cincinnati OH— September 10, 2014) Airway Therapeutics, a biotechnology company working to prevent a debilitating lung condition in extremely premature infants, has secured $4.6 million in Series A financing. CincyTech led the round, with participation from Cincinnati Children’s Hospital Medical …
New Company Formed to Take Cincinnati Children’s Lung Treatment Research to Premature Babies
Airway Therapeutics LLC has been created to commercialize pulmonary therapy research developed at Cincinnati Children’s Hospital Medical Center and has received a $500,000 investment from CincyTech and Cincinnati Children’s Tomorrow Fund. The investments are part of a projected $1.2 million seed-stage funding round led by CincyTech. CincyTech and the Tomorrow Fund each invested $250,000 in …